CAR-T Therapy Cures Stiff Person Syndrome: A Medical Breakthrough in 2026
On April 21, 2026, at the American Academy of Neurology annual meeting, researchers from Kyverna Therapeutics presented data that fundamentally changed the landscape of a disease that had been considered essentially incurable: Stiff Person Syndrome (SPS). The results of the KYSA-8 Phase 2 clinical trial were unequivocal — miv-cel, a CAR-T cell therapy, produced historic outcomes in patients who had exhausted all other treatment options.
What Is Stiff Person Syndrome?
Stiff Person Syndrome is one of the rarest and most misunderstood diseases in neurology. Affecting approximately 1 in 1 million people globally, SPS is a progressive autoimmune neurological condition in which the patient's own immune system attacks specific neurons in the central nervous system — specifically those involved in muscle control and relaxation.
The result is devastating: uncontrolled muscle rigidity that begins in the trunk and progressively spreads to the limbs. Patients experience severe, painful spasms that can be triggered by emotional stress, sudden movement, or even loud noises. As the disease progresses, many patients lose the ability to walk, to perform basic self-care tasks, and to live independently.
The autoimmune mechanism involves antibodies against glutamic acid decarboxylase (GAD65), an enzyme essential for producing GABA — the main inhibitory neurotransmitter in the nervous system. When these antibodies attack GAD65-producing neurons, the inhibitory brake on muscle contraction is removed, leading to the characteristic stiffness and spasms.
SPS is rare enough that many patients wait years for a correct diagnosis, often dismissed as anxiety, psychosomatic disorders, or other neurological conditions. Once diagnosed, the picture was historically bleak: no cure, no disease-modifying treatment, only symptom management that becomes progressively less effective as the disease advances.
The Existing Treatments and Their Limitations
Before 2026, treatment for SPS relied on a handful of approaches, none of which addressed the underlying cause:
Benzodiazepines (diazepam/Valium) — Reduce muscle spasms by enhancing GABA activity, but cause significant sedation and dependency with long-term use, and become progressively less effective.
Baclofen — A muscle relaxant that works similarly, often administered via intrathecal pump directly into the spinal cord in severe cases. Provides symptom relief but not disease modification.
IVIG (intravenous immunoglobulin) — The closest thing to a disease-modifying therapy that existed before 2026. By flooding the system with immunoglobulins, IVIG temporarily reduces the anti-GAD65 antibody activity. It can provide months of symptom relief — but must be repeated every few weeks, costs tens of thousands of dollars per infusion, and doesn't stop the underlying autoimmune process.
Rituximab — An anti-CD20 monoclonal antibody that depletes B cells, the source of the anti-GAD65 antibodies. Has shown some benefit in case studies and small trials, but results have been inconsistent and the effect temporary, as B cells repopulate over time.
The fundamental problem with all existing therapies: they manage symptoms or temporarily suppress the immune attack, but the autoimmune process continues. Patients remain on multiple medications indefinitely, with quality of life progressively deteriorating.
How CAR-T Therapy Works Differently
CAR-T (Chimeric Antigen Receptor T-cell) therapy represents a fundamentally different approach. Instead of suppressing the immune system broadly or blocking specific pathways temporarily, CAR-T aims to precisely eliminate the cells responsible for the autoimmune attack.
In the case of miv-cel (Kyverna's CD19-targeted CAR-T therapy), the process works as follows:
1. Cell collection: T cells (a type of white blood cell) are collected from the patient through a process called leukapheresis.
2. Genetic engineering: In a laboratory, the T cells are genetically modified to express a chimeric antigen receptor (CAR) — a synthetic protein that specifically recognizes CD19, a marker present on B cells.
3. Expansion: The modified T cells are expanded (multiplied) in the laboratory until there are sufficient numbers.
4. Infusion: The engineered CAR-T cells are infused back into the patient in a single treatment.
5. Action: The CAR-T cells circulate through the body, identifying and eliminating CD19-positive B cells — including the specific B cell clones responsible for producing anti-GAD65 antibodies.
The key insight: by eliminating the source of the pathological antibodies (the B cells), miv-cel may not just control SPS symptoms — it could potentially reset the autoimmune response that causes SPS in the first place.
The KYSA-8 Trial: Results That Changed Everything
The KYSA-8 Phase 2 clinical trial enrolled 26 patients with moderate-to-severe SPS who had failed or were inadequately controlled on existing therapies. These were patients with established disease, significant disability, and no other therapeutic options. The primary endpoint was the 25-foot walk test — a standardized measure of walking speed and mobility used in neurological trials.
The results, presented at the AAN annual meeting in April 2026:
81% of patients achieved clinically significant improvement in the 25-foot walk test (defined as ≥20% reduction in walking time) — meaning most patients could walk measurably faster and more easily after treatment.
67% of patients using wheelchairs or walkers abandoned those mobility devices entirely — walking independently for the first time in months or years.
Nearly one-third of patients (approximately 8 of 26) returned to walking at speeds comparable to healthy adults their age — a complete functional recovery by this measure.
All 26 patients were able to discontinue the chronic immunosuppressive medications (primarily IVIG and/or rituximab) they had been using prior to the trial — a significant finding, as these drugs have substantial costs and side effect profiles.
Safety profile: No serious adverse events including cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) — the two most feared complications of CAR-T therapy — were observed at the doses used in the trial.
Why This Is Historically Significant
The KYSA-8 results matter for several reasons that extend beyond SPS itself:
First: They demonstrate that CAR-T therapy — previously used primarily in blood cancers — can be safe and effective in autoimmune neurological diseases. This opens the door for similar approaches in other autoimmune conditions like multiple sclerosis, neuromyelitis optica, and myasthenia gravis.
Second: The depth of response — patients abandoning wheelchairs, returning to normal walking speed — exceeds what any previous SPS treatment has achieved. This isn't incremental improvement; for many patients, it represents functional transformation.
Third: The one-time treatment model challenges the chronic disease management paradigm. If a single infusion can eliminate the disease-causing immune cells and provide durable remission, the economics and quality-of-life implications are transformative compared to lifelong symptom management.
What Comes Next: The Path to Approval
The KYSA-8 results are compelling, but Phase 2 trials are not sufficient for FDA approval. Kyverna Therapeutics will need to demonstrate the results in a larger, controlled Phase 3 trial before seeking FDA approval.
Key questions that Phase 3 trials will need to address:
Durability: The KYSA-8 trial followed patients for 16 weeks. The critical question is how long the remission lasts. Do the B cells repopulate over time and restart the autoimmune process? Are booster treatments needed?
Long-term safety: CAR-T therapy's long-term immunological consequences need extended follow-up. Eliminating B cells affects the broader immune system — patients may need immunoglobulin replacement therapy.
Optimal patient selection: Which SPS patients benefit most from miv-cel? Early-stage vs. advanced disease? Patients with high vs. low anti-GAD65 antibody levels?
Broader autoimmune application: Several other companies are exploring CD19-targeted CAR-T in autoimmune diseases. The SPS results will intensify that research across conditions.
For the approximately 1 in 1 million people living with SPS globally, the KYSA-8 results represent something unprecedented: the realistic prospect of a treatment that doesn't just manage their disease, but may eliminate its cause. For a disease that had offered patients no hope of meaningful recovery, April 2026 marked a turning point.
Impact Table
| Metric | KYSA-8 Result |
|---|---|
| Patients enrolled | 26 |
| Mobility improvement ≥20% | 81% |
| Wheelchair/walker abandonment | 67% |
| Walking at healthy adult speed | ~31% |
| Discontinued previous therapies | 100% |
| Serious adverse events | 0 |
| Follow-up duration | 16 weeks |
Sources
- Science News — New drug for stiff person syndrome restores mobility
- AAN 2026 Annual Meeting — KYSA-8 trial presentation
- Kyverna Therapeutics — miv-cel trial data
- NORD — Stiff Person Syndrome overview
